目的:评价拉米夫定联合胸腺素α1治疗慢性重型肝炎的临床疗效。方法:56例患者分为两组(治疗组、对照组),治疗组在保肝治疗的基础上给予拉米夫定联合胸腺素α1治疗,对照组仅给予保肝治疗。结果:治疗组总胆红素较对照组下降明显,治疗组好转率为53%,对照组为19%,两组比较差异有统计学意义(P<0.005)。结论:拉米夫定联合胸腺素α1慢性重型肝炎能有效降低病死率,且用药安全。 Objective: To evaluate the clinical efficacy of lamivudine combined with thymosin α1 in the treatment of chronic severe hepatitis. Methods: Fifty-six patients were divided into two groups (treatment group and control group). The treatment group was treated with lamivudine combined with thymosin α1 on the basis of hepatoprotective therapy, while the control group was given only hepatoprotective therapy. Results: The total bilirubin in the treatment group decreased significantly compared with the control group. The improvement rate was 53% in the treatment group and 19% in the control group. There was significant difference between the two groups (P <0.005). Conclusion: Lamivudine combined with thymosin α1 chronic severe hepatitis can effectively reduce the mortality and medication safety.